3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow

Despite broader market rebound driven by easing tariff concerns, Vertex Pharmaceuticals (VRTX) has declined 14% in May due to an earnings disappointment linked to illegal generic competition in Russia. The Motley Fool suggests that Vertex is now a buy due to its tariff-resistant business model, promising new drugs like Alyftrek and Journavx, and a lower valuation of 24x forward earnings; however, they also note that Vertex was not one of their top 10 stock picks.

Analysis

Major U.S. stock indexes, including the S&P 500, Nasdaq Composite, and Dow Jones Industrial Average, have rebounded from March and April lows, driven by growing optimism around more manageable import tariff levels following a U.S. deal with the U.K. and an initial agreement with China. Despite this broader market recovery, Vertex Pharmaceuticals (VRTX) experienced a 14% decline in May due to an earnings disappointment linked to sales impact from an illegal generic cystic fibrosis (CF) drug in Russia. However, Vertex is presented as a compelling investment opportunity, primarily due to its status as a tariff-safe haven, with most CF drug production occurring in the U.S., a balanced supply chain, and minimal China exposure. Furthermore, the essential nature of its CF treatments is expected to ensure stable revenue. The company is embarking on a new growth phase, supported by the recent approval of Alyftrek, a new CF drug demonstrating superior performance to its current blockbuster Trikafta, and Journavx, a non-opioid painkiller for moderate-to-severe acute pain, which targets the $125 billion pain management market. Following its recent stock price decline, Vertex trades at 24 times forward earnings estimates, down from over 28 times, which is described as a bargain considering its CF market dominance and new product pipeline. Notwithstanding these positive attributes, The Motley Fool Stock Advisor did not include Vertex Pharmaceuticals in its list of 10 best stocks to buy now.

Key Decisions for Investors

• Investors might consider the recent 14% dip in Vertex Pharmaceuticals' stock, bringing its valuation to 24x forward earnings, as a potential entry point, given the company's strong CF franchise, limited tariff exposure, and new growth catalysts like Alyftrek and Journavx.
• It is advisable to monitor the commercial launch and market penetration of Vertex's newly approved drugs, Alyftrek and Journavx, as their success is pivotal to realizing the projected new era of growth and justifying the current valuation.
• While the fundamental outlook for Vertex appears robust, the fact that it was not selected for The Motley Fool's top 10 stock list suggests investors should weigh the specific bullish case for Vertex against other opportunities and conduct thorough due diligence on the transient nature of the Russian generic issue.